California State Teachers Retirement System Sells 856 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

California State Teachers Retirement System lowered its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 2.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,093 shares of the specialty pharmaceutical company’s stock after selling 856 shares during the quarter. California State Teachers Retirement System owned approximately 0.10% of Collegium Pharmaceutical worth $862,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter worth about $40,000. KBC Group NV grew its holdings in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after acquiring an additional 982 shares during the last quarter. Virtus Fund Advisers LLC grew its holdings in Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 565 shares during the last quarter. FORA Capital LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter worth about $223,000. Finally, Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical during the 4th quarter worth about $230,000.

Collegium Pharmaceutical Stock Down 0.2%

Shares of NASDAQ COLL opened at $30.37 on Wednesday. The firm has a market capitalization of $975.85 million, a PE ratio of 13.09 and a beta of 0.63. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The firm’s 50-day moving average is $28.03 and its 200-day moving average is $29.60.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. During the same period last year, the business posted $1.45 EPS. The firm’s revenue for the quarter was up 22.7% compared to the same quarter last year. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 19th. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $43.75.

Insider Buying and Selling

In related news, CFO Colleen Tupper sold 977 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $29,310.00. Following the transaction, the chief financial officer now owns 164,269 shares of the company’s stock, valued at $4,928,070. This trade represents a 0.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Scott Dreyer sold 2,255 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the sale, the executive vice president now owns 124,421 shares in the company, valued at $3,732,630. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.51% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.